Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia

This is a multi center, randomized, double blind, placebo controlled, fixed dose study of
eszopiclone in pediatric subjects 6-17 years of age, inclusive, with ADHD associated
insomnia. Subjects will be randomized at approximately 1:1:1 to either low dose oral
eszopiclone (1 mg for children ages 6-11 years, 2 mg for adolescents ages 12-17 years), high
dose oral eszopiclone (2 mg for children ages 6-11 years, 3 mg for adolescents ages 12-17
years) or placebo. This study was previously posted by Sepracor Inc. In October 2009,
Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor
Inc's name was changed to Sunovion Pharmaceuticals Inc.